6 Analysts Assess Treace Medical Concepts: What You Need To Know
Portfolio Pulse from Benzinga Insights
Six analysts have recently reviewed Treace Medical Concepts (NASDAQ:TMCI), with mixed opinions. The average 12-month price target is now $17.5, down from $21.75, with a high estimate of $28.00 and a low of $11.00. Analysts from firms like Truist Securities, Morgan Stanley, Stifel, and UBS have adjusted their ratings and price targets. Treace Medical Concepts is a commercial-stage orthopaedic medical device company with a patented procedure for bunion correction. The company has shown a revenue growth rate of 23.3% as of September 30, 2023, but has a net margin of -42.99% and an ROE of -12.17%. Its debt-to-equity ratio is 0.51, below the industry average.
December 22, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have mixed views on TMCI, with a decreased average price target suggesting a bearish outlook. However, strong revenue growth could indicate underlying business strength.
The lowered average price target reflects a bearish sentiment among analysts, which could negatively impact investor confidence and TMCI's stock price in the short term. However, the strong revenue growth rate is a positive sign, and if investors focus on the company's operational performance, it could mitigate some of the negative impact from the analysts' revisions.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100